Evaluating treatments for severe Takayasu arteritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study focuses on patients with severe Takayasu arteritis, a rare chronic inflammatory condition. Patients are classified into three severity levels, and those in the severe category will receive either tocilizumab or adalimumab to determine which treatment is more effective. The study aims to personalize treatment strategies based on individual patient characteristics and disease severity. By comparing the efficacy of these biological agents, the research seeks to improve intervention strategies for severe cases of Takayasu arteritis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. age≥14 years old;
2. active: Kerr score≥ 2;
3. severe:

   1. Blood pressure \> 180/110mmHg;
   2. ≥ 3 branches with the stenotic rate \> 70% involved;
   3. high degree of organ insufficiency: NYHF III\~IV; eGFR (MRDR) 15\~ 60ml/min;

Exclusion Criteria:

1. Severe organ insufficiency;
2. Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;
3. Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;
4. malignant tumors;
5. history of severe drug allergy;
6. successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)

Where it's running

• Department of Rheumatology in Zhongshan hospital, Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Rongyi Chen, PhD
• Email: chenry825@hotmail.com
• Phone: +8615221160538

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Add-on anti-inflammatory therapy for adults with depression and high inflammation

  This study tests whether adalimumab, given with your regular antidepressant Lexapro, can improve depressive symptoms in adults with major depressive disorder and high inflammation.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07845604

• Anticoagulation Plus Tocilizumab for Acute Cerebral Venous Thrombosis

  This study tests whether adding a single dose of tocilizumab to standard blood thinners helps people with acute cerebral venous thrombosis.

  Recruiting Capital Medical University · Beijing, Beijing Municipality · NCT07801638

• Colonic delivery of two antibodies to see if they reach the bloodstream in healthy people

  This early study tests whether guselkumab and adalimumab given directly into the colon can enter the body in healthy adults.

  Recruiting Phase 1 Surmount Services, Inc. · Maroochydore, Queensland · NCT07788807

• Tabellvi for moderate to severe Crohn's disease in Chinese adults

  This real-world, single-arm study tests Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease to see how often side effects occur and whether many patients reach remission by week 26.

  Recruiting Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuyang, Anhui and 6 other locations · NCT07663526

• Adalimumab treatment for adults with non-infectious uveitis

  This trial tests whether TyboWe Adalimumab can help adults with non-infectious uveitis who are already on steroids.

  Recruiting Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tianjin, Tianjin Municipality · NCT07663331

• Linvoseltamab with pre-dose Tocilizumab to reduce CRS in adults with relapsed/refractory multiple myeloma

  This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome in adults with relapsed/refractory multiple myeloma who have had at least four prior therapies.

  Recruiting at 7 sites Phase 4 Regeneron Pharmaceuticals · Los Angeles, California and 6 other locations · NCT07609940

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.